MX2007006102A - Agentes anti-cancer de union a tubulina y profarmacos de los mismos. - Google Patents

Agentes anti-cancer de union a tubulina y profarmacos de los mismos.

Info

Publication number
MX2007006102A
MX2007006102A MX2007006102A MX2007006102A MX2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A MX 2007006102 A MX2007006102 A MX 2007006102A
Authority
MX
Mexico
Prior art keywords
tubulin binding
prodrugs
cancer agents
anti cancer
binding anti
Prior art date
Application number
MX2007006102A
Other languages
English (en)
Spanish (es)
Inventor
Mark Matteucci
Jian-Xin Duan
Xiaohong Cai
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of MX2007006102A publication Critical patent/MX2007006102A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007006102A 2004-11-22 2005-11-17 Agentes anti-cancer de union a tubulina y profarmacos de los mismos. MX2007006102A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63042204P 2004-11-22 2004-11-22
US72692805P 2005-10-14 2005-10-14
PCT/US2005/042095 WO2006057946A2 (en) 2004-11-22 2005-11-17 Tubulin binding anti cancer agents and prodrugs thereof

Publications (1)

Publication Number Publication Date
MX2007006102A true MX2007006102A (es) 2007-07-11

Family

ID=36498450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006102A MX2007006102A (es) 2004-11-22 2005-11-17 Agentes anti-cancer de union a tubulina y profarmacos de los mismos.

Country Status (10)

Country Link
US (1) US20090042820A1 (cg-RX-API-DMAC7.html)
EP (1) EP1819338A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008520719A (cg-RX-API-DMAC7.html)
KR (1) KR20070086595A (cg-RX-API-DMAC7.html)
AU (1) AU2005309761A1 (cg-RX-API-DMAC7.html)
CA (1) CA2587210A1 (cg-RX-API-DMAC7.html)
IL (1) IL183212A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006102A (cg-RX-API-DMAC7.html)
NO (1) NO20073211L (cg-RX-API-DMAC7.html)
WO (1) WO2006057946A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CA2655913A1 (en) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US8765690B2 (en) 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2008151253A1 (en) * 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
ES2884674T3 (es) 2008-10-21 2021-12-10 Immunogenesis Inc Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US10037382B2 (en) 2012-10-29 2018-07-31 Kyocera Corporation Surface acoustic wave sensor
CA2924843A1 (en) * 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US10131683B2 (en) 2014-07-17 2018-11-20 Molecular Templates, Inc. TH-302 solid forms and methods related thereto
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
BR112017021167A2 (pt) * 2015-04-02 2018-07-03 Obi Pharma, Inc. composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020079652A1 (en) * 2018-10-17 2020-04-23 Insilico Medicine Hong Kong Limited Kinase inhibitors
CN115403483B (zh) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
DE60129536T2 (de) * 2000-03-10 2008-06-19 Baylor University, Waco Tubulin bindende liganden
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
DE60336646D1 (de) * 2003-08-07 2011-05-19 Nat Health Research Institutes Indol-Verbindungen als Inhibitoren der Tubulin-Polymerisation zur Behandlung von angiogenesisbezogenen Erkrankungen
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds

Also Published As

Publication number Publication date
IL183212A0 (en) 2008-04-13
AU2005309761A1 (en) 2006-06-01
WO2006057946A2 (en) 2006-06-01
US20090042820A1 (en) 2009-02-12
EP1819338A4 (en) 2009-11-04
NO20073211L (no) 2007-08-21
EP1819338A2 (en) 2007-08-22
JP2008520719A (ja) 2008-06-19
KR20070086595A (ko) 2007-08-27
WO2006057946A3 (en) 2007-07-05
CA2587210A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
MX2007006102A (es) Agentes anti-cancer de union a tubulina y profarmacos de los mismos.
IL180677A0 (en) Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer
PL1874821T3 (pl) Kombinacja przeciwciał i glikokortykoidów do leczenia raka
IL241756A0 (en) Preparations and methods for the treatment of diseases of safty tumors
WO2006128129A3 (en) Method for treating cancer
IL180729A0 (en) Compounds and methods for treatment of cancer
IL187238A0 (en) Compositions and methods for treating hyperproliferative epidermal diseases
WO2007053573A3 (en) Treatment of cancer with sorafenib
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
IL181304A0 (en) Dihydropteridinones for the treatment of cancer diseases
IL176919A0 (en) Methods and compositions for treating cancer
WO2007101148A3 (en) Hexose compounds to treat cancer
IL178920A0 (en) Treatment for pancreatic cancer
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
IL177104A (en) Ccx-ckr2 binding agents for treatment of cancer and arthritis and for wound healing
IL161899A0 (en) Kit for treatment of cancer
IL189376A0 (en) Combinations comprising dmxaa for the treatment of cancer
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
WO2007137196A3 (en) Tubulin binding anti cancer compounds and prodrugs thereof
ZA200704901B (en) Tubulin binding anti cancer agents and prodrugs thereof
HK1109060A (en) Combinations of therapeutic agents for treating cancer
GB0423273D0 (en) Treatment of cancer
HK1097275A (en) Compounds and methods for treatment of cancer
GB0404571D0 (en) Methods for treating interstitial cystitis and related compounds and compositions
HK1110303A (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal